BR112015022391A8 - inibidores de domínio bromo tetracíclico - Google Patents

inibidores de domínio bromo tetracíclico Download PDF

Info

Publication number
BR112015022391A8
BR112015022391A8 BR112015022391A BR112015022391A BR112015022391A8 BR 112015022391 A8 BR112015022391 A8 BR 112015022391A8 BR 112015022391 A BR112015022391 A BR 112015022391A BR 112015022391 A BR112015022391 A BR 112015022391A BR 112015022391 A8 BR112015022391 A8 BR 112015022391A8
Authority
BR
Brazil
Prior art keywords
tetracyclic
domain inhibitors
bromine domain
formula
bromine
Prior art date
Application number
BR112015022391A
Other languages
English (en)
Other versions
BR112015022391A2 (pt
BR112015022391B1 (pt
Inventor
Bogdan Andrew
Liu Dachun
S Sheppard George
H Holms James
Marjanovic Jasmina
Pratt John
D Dietrich Justin
F Mcdaniel Keith
Wang Le
A Hasvold Lisa
A Mantei Robert
D Fidanze Steven
Dai Yujia
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112015022391A2 publication Critical patent/BR112015022391A2/pt
Publication of BR112015022391A8 publication Critical patent/BR112015022391A8/pt
Publication of BR112015022391B1 publication Critical patent/BR112015022391B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

resumo “inibidores de domínio bromo tetracíclico” a presente invenção provê compostos da formula (i): (i) em que r1, r2, r6, y1, y2, y3, a1, a2, a3, e a4 apresentam qualquer um dos valores definidos no relatório descritivo e sais farmaceuticamente aceitáveis dos mesmos, que são úteis como agentes no tratamento de doenças e condições, inclu-indo doenças inflamatórias, câncer e aids. também são providas composições farmacêuticas compreendendo um ou mais compostos da fórmula (i).
BR112015022391-5A 2013-03-12 2014-03-12 Compostos inibidores do domínio bromo tetracíclico, composição farmacêutica que compreende os referidos compostos e usos terapêuticos dos mesmos BR112015022391B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361777797P 2013-03-12 2013-03-12
US61/777,797 2013-03-12
US201461928779P 2014-01-17 2014-01-17
US61/928,779 2014-01-17
PCT/CN2014/000258 WO2014139324A1 (en) 2013-03-12 2014-03-12 Tetracyclic bromodomain inhibitors

Publications (3)

Publication Number Publication Date
BR112015022391A2 BR112015022391A2 (pt) 2017-07-18
BR112015022391A8 true BR112015022391A8 (pt) 2019-11-26
BR112015022391B1 BR112015022391B1 (pt) 2021-12-21

Family

ID=51535867

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022391-5A BR112015022391B1 (pt) 2013-03-12 2014-03-12 Compostos inibidores do domínio bromo tetracíclico, composição farmacêutica que compreende os referidos compostos e usos terapêuticos dos mesmos

Country Status (22)

Country Link
US (5) US10035800B2 (pt)
EP (2) EP3539962A1 (pt)
JP (2) JP6419735B2 (pt)
KR (1) KR102224992B1 (pt)
CN (2) CN105026403B (pt)
AR (1) AR095266A1 (pt)
AU (2) AU2014231563A1 (pt)
BR (1) BR112015022391B1 (pt)
CA (1) CA2903910C (pt)
CR (1) CR20150474A (pt)
DO (1) DOP2015000216A (pt)
HK (1) HK1217102A1 (pt)
IL (1) IL241010B (pt)
MX (1) MX363913B (pt)
PE (1) PE20151788A1 (pt)
PH (1) PH12015502004A1 (pt)
RU (1) RU2015143192A (pt)
SG (1) SG11201507402WA (pt)
TW (1) TWI635087B (pt)
UY (1) UY35395A (pt)
WO (1) WO2014139324A1 (pt)
ZA (1) ZA201506477B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2861566T (pt) 2012-06-13 2017-02-08 Hoffmann La Roche Novos diazaspirocicloalcanos e azaspirocicloalcanos
UA116547C2 (uk) 2012-09-25 2018-04-10 Ф. Хоффманн-Ля Рош Аг Біциклічні похідні
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AU2014231563A1 (en) * 2013-03-12 2015-09-17 Abbvie Inc. Tetracyclic bromodomain inhibitors
JP6243003B2 (ja) 2013-03-15 2017-12-06 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Betタンパク質阻害剤としての三環式複素環
CA2917319A1 (en) 2013-07-08 2015-01-15 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
UA119347C2 (uk) 2014-03-26 2019-06-10 Ф. Хоффманн-Ля Рош Аг Конденсовані [1,4]діазепінові сполуки як інгібітори продукції аутотаксину (atх) та лізофосфатидилової кислоти (lpa)
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
DK3674302T3 (da) 2014-04-23 2023-04-03 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner
CA2955074A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
RU2017104898A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Дигидроптеридиноновые производные и их применения
EP3194406B8 (en) 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
CN107108613B (zh) 2014-11-10 2020-02-25 基因泰克公司 布罗莫结构域抑制剂及其用途
MA40943A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3250571B1 (en) 2015-01-29 2022-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
CA2980266A1 (en) 2015-03-30 2016-10-06 Jubilant Biosys Limited Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180043837A (ko) 2015-09-04 2018-04-30 에프. 호프만-라 로슈 아게 페녹시메틸 유도체
CA2997531A1 (en) 2015-09-09 2017-03-16 Jubilant Biosys Limited Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors
MX2018003031A (es) 2015-09-11 2018-08-01 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas.
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
CA2983782A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
WO2017050791A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
CA2984585A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
CN107922412B (zh) 2015-09-24 2021-02-23 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
BR112018009798A8 (pt) * 2015-11-25 2019-02-26 Dana Farber Cancer Inst Inc inibidores de bromodomínio bivalentes e usos dos mesmos
PL3442972T3 (pl) 2016-04-15 2020-07-27 Abbvie Inc. Inhibitory bromodomeny
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
KR20190075131A (ko) 2016-11-10 2019-06-28 뤄신 파마슈티컬 (상하이) 컴퍼니 리미티드 질소 함유 거대 고리계 화합물, 이의 제조 방법, 약물 조성물 및 용도
WO2018130174A1 (zh) * 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
CR20190423A (es) 2017-03-16 2019-11-01 Hoffmann La Roche Nuevos compuestos biciclícos como inhibidores dobles de atx/ca
WO2018188047A1 (en) * 2017-04-14 2018-10-18 Abbvie Inc. Bromodomain inhibitors
CN110305123B (zh) * 2018-03-27 2021-12-10 海创药业股份有限公司 一种含有金刚烷的化合物及其在治疗癌症中的用途
CN110865130B (zh) * 2018-08-27 2023-08-22 北京海晶生物医药科技有限公司 一种盐酸奥洛他定及其有关物质的检测方法
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
AU2019372121A1 (en) 2018-10-30 2021-05-27 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
CN109394768B (zh) * 2018-12-10 2019-08-23 牡丹江医学院 一种治疗湿疹的药物及其制备方法
CN111377934B (zh) * 2018-12-29 2023-01-24 中国科学院上海药物研究所 一类杂环化合物,其制备及用途
AU2020242411A1 (en) * 2019-03-17 2021-11-11 Shanghai Ringene Biopharma Co., Ltd. Pyrrole amidopyridone compound, preparation method therefor and use thereof
AU2020299592A1 (en) 2019-07-02 2022-02-17 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
WO2021121276A1 (zh) * 2019-12-17 2021-06-24 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CA3214399A1 (en) * 2021-04-09 2022-10-13 Frank Perabo Treatment of cancer with kdm4 inhibitors
CA3224302A1 (en) * 2021-06-29 2023-01-05 Tay Therapeutics Limited Pyrrolopyridone derivatives useful in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1887008B1 (en) 2005-05-30 2021-04-21 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and a medicinal use thereof
EP2079740B1 (en) * 2006-11-01 2012-12-05 Vertex Pharmaceuticals, Inc. Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
GB0919426D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011054845A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
EP2585465B1 (en) * 2010-06-22 2014-11-12 GlaxoSmithKline LLC Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9422292B2 (en) * 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AU2014231563A1 (en) * 2013-03-12 2015-09-17 Abbvie Inc. Tetracyclic bromodomain inhibitors

Also Published As

Publication number Publication date
IL241010B (en) 2019-01-31
US20180298003A1 (en) 2018-10-18
RU2015143192A (ru) 2017-04-17
CN105026403A (zh) 2015-11-04
EP2970330A1 (en) 2016-01-20
US20190389861A1 (en) 2019-12-26
TW201512200A (zh) 2015-04-01
KR20150126050A (ko) 2015-11-10
CN105026403B (zh) 2018-05-18
KR102224992B1 (ko) 2021-03-10
UY35395A (es) 2014-10-31
EP2970330B1 (en) 2019-04-17
JP2016510772A (ja) 2016-04-11
BR112015022391A2 (pt) 2017-07-18
WO2014139324A1 (en) 2014-09-18
US20210070756A1 (en) 2021-03-11
DOP2015000216A (es) 2015-11-30
PE20151788A1 (es) 2015-12-20
MX363913B (es) 2019-04-08
AU2018203833A1 (en) 2018-06-21
AU2014231563A1 (en) 2015-09-17
IL241010A0 (en) 2015-11-30
HK1217102A1 (zh) 2016-12-23
MX2015012006A (es) 2015-12-01
US10035800B2 (en) 2018-07-31
CR20150474A (es) 2015-12-14
TWI635087B (zh) 2018-09-11
SG11201507402WA (en) 2015-10-29
JP2019014748A (ja) 2019-01-31
BR112015022391B1 (pt) 2021-12-21
CA2903910A1 (en) 2014-09-18
CN108440528A (zh) 2018-08-24
AR095266A1 (es) 2015-09-30
ZA201506477B (en) 2020-02-26
EP3539962A1 (en) 2019-09-18
CA2903910C (en) 2023-08-15
JP6419735B2 (ja) 2018-11-07
US20200291027A1 (en) 2020-09-17
EP2970330A4 (en) 2016-10-19
PH12015502004A1 (en) 2016-01-11
US20160039821A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
BR112015022391A2 (pt) inibidores de domínio bromo tetracíclico
BR112015022674A2 (pt) inibidores de bromodomínio
BR112015022551A2 (pt) inibidores de amido pirrol
BR112015032710A2 (pt) inibidores de bromodomínio
BR112015022861A8 (pt) inibidores de bromodomínio
UY39630A (es) Inhibidores de bromodominios
BR112014031234A2 (pt) derivados de piridinona e piridazinona
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112018071216A2 (pt) inibidores de bromodomínios
MX2016007346A (es) Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
MX2014012695A (es) Derivados de isoindolona.
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112017014970A2 (pt) macrociclos de piridazinona como inibidores de irak e usos dos mesmos
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
BR112015020834A2 (pt) novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
BR112019007631A2 (pt) inibidores de bromodomínios
BR112019007591A2 (pt) inibidores de bromodomínios
BR112015006220A2 (pt) agentes antibacterianos de tetrahidroquinolina tricíclica
BR112014009217A2 (pt) antibacterianos à base de fenicol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2014, OBSERVADAS AS CONDICOES LEGAIS.